Evidence map›Paper›PMID 37752234›Full record

ArticleOncogene2023

Blockade of de novo pyrimidine biosynthesis triggers autophagic degradation of oncoprotein FLT3-ITD in acute myeloid leukemia.

Hui Ma, Jiayan Cui, Zehui Liu, Wenqing Fang, Sisi Lu, Shuying Cao, Yuanyuan Zhang, Ji-An Chen, Lixue Lu, Qiong Xie and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Case Report: Pediatric AML withFrontiers in oncology · 2025
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Hui Ma *Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 200237, Shanghai, China.
Jiayan Cui *Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 200237, Shanghai, China.
Zehui Liu *Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 200237, Shanghai, China.
Wenqing FangShanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 200237, Shanghai, China.
Sisi LuShanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 200237, Shanghai, China.
Shuying CaoShanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 200237, Shanghai, China.
Yuanyuan ZhangShanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 200237, Shanghai, China.
Ji-An ChenDepartment of Medicinal Chemistry, School of Pharmacy, Fudan University, 201203, Shanghai, China.
Lixue LuDepartment of Medicinal Chemistry, School of Pharmacy, Fudan University, 201203, Shanghai, China.
Qiong XieDepartment of Medicinal Chemistry, School of Pharmacy, Fudan University, 201203, Shanghai, China.
Yonghui WangDepartment of Medicinal Chemistry, School of Pharmacy, Fudan University, 201203, Shanghai, China.
Ying HuangNMPA Key Laboratory of Rapid Drug Inspection Technology, Guangdong Institute for Drug Control, 510663, Guangzhou, China.
Kongfei LiDepartment of Hematology, People's Hospital Affiliated to Ningbo University, 315000, Ningbo, China.
Hongyan TongDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, 310003, Hangzhou, China.
Jin HuangShanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 200237, Shanghai, China. huangjin@ecust.edu.cn.
Weiqiang LuShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 200241, Shanghai, China. wqlu@bio.ecnu.edu.cn.ORCID 0000-0003-1349-6597
East China University of Science and Technology · CNFudan University · CNEast China Normal University · CNFirst Affiliated Hospital Zhejiang University · CNGuangdong Institute for Drug Control · CNNingbo University · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81973362
6 · The paper itself

Abstract

The internal tandem duplication of the FMS-like tyrosine kinase 3 (FLT3-ITD) is one of the most frequent genetic alterations in acute myeloid leukemia (AML). Limited and transient clinical benefit of FLT3 kinase inhibitors (FLT3i) emphasizes the need for alternative therapeutic options for this subset of myeloid malignancies. Herein, we showed that FLT3-ITD mutant (FLT3-ITD

Indexed as

Dihydroorotate DehydrogenaseLeukemia, Myeloid, AcuteAnimalsAutophagyBenzothiazolesfms-Like Tyrosine Kinase 3HumansMiceMutationOncogene ProteinsPhenylurea CompoundsProtein Kinase InhibitorsPyrimidinesBenzothiazolesDihydroorotate DehydrogenaseFLT3 protein, humanfms-Like Tyrosine Kinase 3Oncogene ProteinsPhenylurea CompoundsProtein Kinase InhibitorsPyrimidinesquizartinib

Identifiers

PMID37752234
OpenAlexW4387055558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.